Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.37 |
| ▸ | CNR1 | P21554 | 10/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18869370 | 1.00 | CNR2 (0.37) | CNR2CNR1ESR1ESR2TDP1 | |
| SCHEMBL21191796 | 0.98 | CNR2 (0.38) | CNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL21884674 | 0.98 | CNR2 (0.38) | CNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL21191600 | 0.98 | CNR2 (0.38) | CNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL22024290 | 0.97 | CNR2 (0.36) | CNR2CNR1ESR1ESR2TDP1 | |
| SCHEMBL19738148 | 0.95 | ESR1 (0.35) | CNR2CNR1ESR1ESR2TDP1 | |
| SCHEMBL21718495 | 0.92 | CNR2 (0.36) | CNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL19738659 | 0.92 | ESR1 (0.33) | CNR2CNR1ESR1ESR2 | |
| SCHEMBL19738625 | 0.88 | ESR1 (0.33) | CNR2CNR1ESR1ESR2 | |
| SCHEMBL19738629 | 0.85 | CNR2 (0.47) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336735-B2 | Small molecule inhibitors of fibrosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170362211-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336735-B2 | Small molecule inhibitors of fibrosis | MMP1, COL2A1, MMP8 | CNR2 3947/4885CNR1 4011/4885ESR1 3730/4885 |
| US-20170362211-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | MMP1, COL2A1, MMP8 | CNR2 3947/4885CNR1 4011/4885ESR1 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.